Company
Amgen
Amgen has 47 drugs tracked on RxWires: 7 post-market, 10 in Phase 3, 12 in Phase 2, 4 in Phase 1/2, 12 in Phase 1.
- Ticker
- AMGN
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Etanercept via Autoinjector A | Post-Market | Rheumatoid Arthritis |
| Etanercept | Post-Market | Psoriasis |
| Evolocumab | Post-Market | Cardiovascular Disease |
| Traditional Vitamin D Therapy | Post-Market | Hyperparathyroidism, Secondary |
| Denosumab | Post-Market | Giant Cell Tumor of Bone |
| Erenumab | Post-Market | Migraine |
| Anakinra (r-metHuIL-1ra) | Post-Market | Rheumatoid Arthritis |
| Darbepoetin alfa | Phase 3 | Anemia in Chronic Kidney Disease Patients Not on Dialysis |
| Maridebart cafraglutide | Phase 3 | Obesity |
| Sotorasib | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) |
| Inebilizumab | Phase 3 | Autoimmune Hepatitis |
| Tarlatamab | Phase 3 | Extensive-Stage Small-Cell Lung Cancer |
| Apremilast | Phase 3 | Behçet's Disease |
| Dazodalibep | Phase 3 | Sjogren's Syndrome |
| Erenumab Dose 1 | Phase 3 | Migraine |
| Bemarituzumab | Phase 3 | Gastric Cancer |
| ABP 501 | Phase 3 | Arthritis, Rheumatoid |
| Blinatumomab | Phase 2 | B Precursor Acute Lymphoblastic Leukemia |
| filgrastim | Phase 2 | Breast Cancer |
| Panitumumab + FOLFIRI | Phase 2 | Metastatic Colorectal Cancer |
| Doxycycline 50Mg Tablet | Phase 2 | Skin Toxicity |
| HPN-100 | Phase 2 | Cirrhosis |
| AMG 301 | Phase 2 | Chronic Migraine or Episodic Migraine |
| Gemcitabine | Phase 2 | Cancer of Pancreas |
| Erenumab-Aooe | Phase 2 | Trigeminal Neuropathy |
| Panitumumab | Phase 2 | Colon Cancer |
| Filgrastim-SD/01 | Phase 2 | Non-small Cell Lung Cancer |
| RCHOP | Phase 2 | Richter Syndrome |
| Carfilzomib | Phase 2 | Multiple Myeloma |
| CCX 354-C | Phase 1/2 | Rheumatoid Arthritis |
| AMG 510 | Phase 1/2 | Non Small Cell Lung Cancer |
| Efavaleukin alfa | Phase 1/2 | Rheumatoid Arthritis RA |
| Acapatamab | Phase 1/2 | Metastatic Castration-resistant Prostate Cancer |
| AMG 780 | Phase 1 | Advanced Solid Tumors |
| AMG 691 | Phase 1 | Asthma |
| Xaluritamig | Phase 1 | Ewing Sarcoma |
| Romosozumab | Phase 1 | Osteopenia |
| AMG 853 | Phase 1 | Asthma |
| AMG 319 | Phase 1 | Cancer |
| AMG 701 | Phase 1 | Relapsed/Refractory Multiple Myeloma |
| AMG 509 | Phase 1 | Prostate Cancer |
| Talimogene Laherparepvec | Phase 1 | Carcinoma of the Head and Neck |
| Imlygic | Phase 1 | NF1 |
| Caffeine | Phase 1 | Atopic Dermatitis |
| Anvumetostat | Phase 1 | Thoracic Tumors |
| Evolocumab 140 MG/ML [Repatha] | Not Applicable | Coronary Artery Disease |
| Romiplostim (formerly AMG 531) | Not Applicable | Hematology |
Latest
Follow Amgen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.